Gilead Sciences (US.GILD)
Capital Allocation Audit · Period: 2010 – 2026
Key Metrics
US.GILD · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 95.4% | → |
| ROE | 8.6% | ↑ |
| Cash Conversion | 125.9% | ↓ |
| D/E Ratio | 0.94 | ↑ |
| Gross Margin | 79.2% | → |
US.GILD (Gilead Sciences) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 95.4% → ROE 8.6% ↑ Cash Conversion 125.9% ↓ D/E Ratio 0.94 ↑ Gross Margin 79.2% →
Key Metrics
US.GILD (Gilead Sciences) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 95.4% →ROE 8.6% ↑Cash Conversion 125.9% ↓D/E Ratio 0.94 ↑Gross Margin 79.2% →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies